Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

78.97
+1.121.44%
Post-market: 79.220.2500+0.32%19:59 EDT
Volume:12.92M
Turnover:1.02B
Market Cap:198.72B
PE:11.72
High:79.04
Open:78.03
Low:77.66
Close:77.85
Loading ...

BUZZ-US drugmakers fall as Trump threatens tariffs again

Reuters
·
09 Apr

Gilead Sciences Down 3%, Amgen Down 2.9%, Pfizer Down 2.7%

THOMSON REUTERS
·
09 Apr

Drugmakers Down Premarket After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

Dow Jones
·
09 Apr

BUZZ-European healthcare drops as Trump says tariffs on sector coming soon

Reuters
·
09 Apr

Merck & Co., Inc. (MRK): Among Defensive Stocks Billionaire Ken Fisher is Betting On

Insider Monkey
·
09 Apr

Apple, Nike Share Losses Lead Dow's 250-Point Fall

Dow Jones
·
09 Apr

Theratechnologies Gets FDA Approval for Prior Approval Supplement of Abdominal Fat Reduction Treatment

MT Newswires Live
·
08 Apr

Theratechnologies Receives FDA Approval for EGRIFTA SV

MT Newswires
·
08 Apr

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

GlobeNewswire
·
08 Apr

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

StockStory
·
08 Apr

Hengrui Medicine Grants Merck Licensing Rights to Fertility Drug

MT Newswires Live
·
08 Apr

2 Reasons to Like MRK (and 1 Not So Much)

StockStory
·
07 Apr

Tariffs Pose $46 Billion Risk to Pharmaceutical Industry -- Analysis

Dow Jones
·
05 Apr

Stock Track | Merck Plummets 5% as Trump Threatens New Tariffs on Pharmaceutical Sector

Stock Track
·
05 Apr

Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs

THOMSON REUTERS
·
04 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Oil companies, US big banks, fintechs

Reuters
·
04 Apr

BUZZ-US drugmakers fall after Trump's new tariff warnings

Reuters
·
04 Apr

Chinese Drug Evaluation Body Accepts Merck's Application for Clesrovimab

MT Newswires Live
·
04 Apr